Granisetron intranasal - Maxinase Life Sciences

Drug Profile

Granisetron intranasal - Maxinase Life Sciences

Alternative Names: Granisetron Hydrochloride Nasal Spray (GNS) - Maxinase Life Sciences

Latest Information Update: 04 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Maxinase Life Sciences
  • Class Analgesics; Antiemetics; Azabicyclo compounds; Indazoles; Small molecules
  • Mechanism of Action Serotonin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Chemotherapy-induced nausea and vomiting

Most Recent Events

  • 31 Dec 2015 Maxinase Life Sciences completes a phase I trial in Chemotherapy induced nausea and vomiting (In volunteers) in Taiwan (Intranasal) (NCT02563951)
  • 16 Sep 2015 Maxinase Life Sciences plans a phase I trial in Healthy volunteers in Taiwan (NCT02563951)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top